Harrow, Inc. Common Stock (HROW) Stock Price

HROWStock

$27.28−28.06%52W

Market Cap$1.02B

P/E—

PEG Ratio—

Div yield—

Beta0.14

HROW Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-37.93%

Price vs S&P 500 (4W)-18.25%

VGM Score45.27

P/CF (Annual)23.31x

Book Value / Share (Quarterly)$0.41

P/TBV (Annual)224.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.39%

Cash Flow / Share (Quarterly)$-0.35

Price vs S&P 500 (YTD)-56.25%

Gross Margin (TTM)73.28%

Net Profit Margin (TTM)-13.51%

EPS (TTM)$-1.00

10-Day Avg Trading Volume0.68M

EPS Excl Extra (TTM)$-1.00

Revenue Growth (5Y)40.99%

EPS (Annual)$-0.14

ROI (Annual)-1.74%

Gross Margin (Annual)75.05%

Net Profit Margin (5Y Avg)-14.03%

Cash / Share (Quarterly)$2.24

Revenue Growth QoQ (YoY)10.85%

ROA (Last FY)-1.29%

Revenue Growth TTM (YoY)21.05%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-55.97%

Operating Margin (TTM)-3.81%

Cash Flow / Share (Annual)$1.15

P/B Ratio67.28x

P/B Ratio (Quarterly)104.15x

Net Income / Employee (Annual)$-13,800

EV / Revenue (TTM)4.47x

Net Interest Coverage (TTM)0.94x

ROA (TTM)-9.31%

EPS Growth QoQ (YoY)-5.63%

EV / EBITDA (TTM)89.07x

EPS Incl Extra (Annual)$-0.14

Current Ratio (Annual)2.20x

Quick Ratio (Quarterly)2.00x

3-Month Avg Trading Volume0.63M

52-Week Price Return-28.06%

EV / Free Cash Flow (Annual)28.79x

Revenue / Employee (TTM)$738,900

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)3.76x

Asset Turnover (Annual)0.68x

52-Week High$54.85

Operating Margin (5Y Avg)3.04%

EPS Excl Extra (Annual)$-0.14

CapEx CAGR (5Y)5.08%

Tangible BV CAGR (5Y)-24.83%

26-Week Price Return-28.02%

Quick Ratio (Annual)1.93x

13-Week Price Return-41.52%

Total Debt / Equity (Annual)4.64x

Current Ratio (Quarterly)2.24x

Enterprise Value$1.23B

Revenue / Share Growth (5Y)31.46%

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)5.88%

Revenue / Employee (Annual)$730,000

Inventory Turnover (Annual)5.61x

Pretax Margin (Annual)-0.50%

Cash / Share (Annual)$1.96

3-Month Return Std Dev43.32%

Gross Margin (5Y Avg)73.23%

Net Income / Employee (TTM)$-99,800

EBITDA CAGR (5Y)62.32%

EBITDA Interim CAGR (5Y)39.57%

ROE (Last FY)-9.80%

Net Interest Coverage (Annual)-0.45x

EPS Basic Excl Extra (Annual)$-0.14

P/FCF (TTM)23.39x

Receivables Turnover (TTM)2.79x

EV / Free Cash Flow (TTM)32.75x

Total Debt / Equity (Quarterly)19.24x

EPS Incl Extra (TTM)$-1.00

Receivables Turnover (Annual)2.40x

ROI (TTM)-12.27%

P/S Ratio (TTM)3.71x

Pretax Margin (5Y Avg)-13.57%

Revenue / Share (Annual)$7.41

Tangible BV / Share (Annual)$0.06

Forward P/E21.43x

Price vs S&P 500 (52W)-43.59%

Year-to-Date Return-44.33%

5-Day Price Return-6.29%

EPS Normalized (Annual)$-0.14

ROA (5Y Avg)-8.17%

Net Profit Margin (Annual)-1.89%

Month-to-Date Return-11.43%

Cash Flow / Share (TTM)$-0.15

EBITD / Share (Annual)$0.67

Operating Margin (Annual)8.36%

LT Debt / Equity (Annual)4.64x

P/CF (TTM)163.57x

ROI (5Y Avg)-9.96%

LT Debt / Equity (Quarterly)19.24x

EPS Basic Excl Extra (TTM)$-1.00

P/TBV (Quarterly)224.79x

P/B Ratio (Annual)34.60x

Inventory Turnover (TTM)5.17x

Pretax Margin (TTM)-12.13%

Book Value / Share (Annual)$1.41

Price vs S&P 500 (13W)-44.21%

Beta0.14x

P/FCF (Annual)23.92x

Revenue / Share (TTM)$7.38

ROE (TTM)-103.86%

52-Week Low$26.96

vGradeD

gGradeB

mGradeD

vgmGradeC

HROW Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.24	-$0.46	-91.67%(-$0.22)
Q1 2026	May 11, 2026	-$0.33	-$0.74	-124.24%(-$0.41)
Q4 2025	Mar 2, 2026	$0.47	$0.27	-43.68%(-$0.21)
Q3 2025	Nov 10, 2025	$0.29	$0.33	+13.79%(+$0.04)
Q2 2025	Aug 11, 2025	$0.04	$0.24	+585.71%(+$0.21)

HROW Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HROWHarrow, Inc. Common Stock	D	B	D	3.7x	21.1%	73.3%	—	$27.28
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Harrow, Inc. Common Stock

Harrow Inc is a specialty pharmaceutical company that develops and commercializes ophthalmic medications for the U.S. market, including branded products like Iheezo, Vevye, and Maxitrol. The company generates revenue through its Branded segment and ImprimisRx platform, while advancing a clinical pipeline targeting conditions such as dry eye disease, glaucoma, and cataracts across both front and back-of-the-eye indications.

HROW Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.32

Revenue estimate$99.07M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

HROW Insider Transactions

SellAug 14, 2026
SHOJAEI AMIR
Officer
Shares: 11,250Value: $450,000

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

ECVTEcovyst Inc.Chemicals
ODDODDITY Tech Ltd. Class A Ordinary SharesCosmetics & Toiletries
IMTXImmatics N.V. Ordinary SharesBiological Products
REPLReplimune Group, Inc.Biological Products
GPREGreen Plains, Inc.Industrial Chemicals
VORVor Biopharma Inc. Common StockBiological Products
MGTXMeiraGTx Holdings plc Ordinary SharesBiological Products
QDELQuidelOrtho Corporation Common StockIn Vitro Diagnostics

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$26.96

High$54.85